{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T11:24:35Z","timestamp":1787397875878,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04308-6","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:01:46Z","timestamp":1775304106000},"page":"4061-4074","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of nivolumab-based combination therapies (with ipilimumab or binimetinib) in patients with microsatellite-stable and microsatellite-instability-high metastatic colorectal cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"28","author":[{"given":"Hussain","family":"Abbas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humayou","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafsa","family":"Shuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazi Uddin","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. N. U.","family":"Muskan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rithik Kumar","family":"Khiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umer","family":"Wamiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Elezeh","family":"Sabahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahzam Khan","family":"Ghori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Shah Hussain","family":"Jafry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4487-5223","authenticated-orcid":false,"given":"Muhammad Liaquat","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"issue":"3","key":"4308_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021).Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209\u2013249.https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"4308_CR2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669\u201385. https:\/\/doi.org\/10.1001\/jama.2021.0106.","journal-title":"JAMA"},{"issue":"1","key":"4308_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07656-w","volume":"20","author":"H Rumpold","year":"2020","unstructured":"Rumpold, H., Nieders\u00fc\u00df-Beke, D., Heiler, C., Falch, D., Schmitt, M., Greil, R., et al. (2020).Prediction of mortality in metastatic colorectal cancer in a real-life population: A multicenterexplorative analysis. BMC Cancer, 20(1), 1149.https:\/\/doi.org\/10.1186\/s12885-020-07656-w.","journal-title":"BMC Cancer"},{"issue":"11","key":"4308_CR4","first-page":"735","volume":"16","author":"F Battaglin","year":"2018","unstructured":"Battaglin, F., Naseem, M., Lenz, H. J., Salem, M. E. (2018). Microsatellite instability in colorectalcancer: Overview of its clinical significance and novel perspectives. Clinical Advances inHematology & Oncology, 16(11), 735\u2013745.","journal-title":"Clin Adv Hematol Oncol"},{"key":"4308_CR5","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ejca.2022.07.020","volume":"175","author":"J Taieb","year":"2022","unstructured":"Taieb J, Svrcek M, Cohen R, Basile D, Tougeron D, Phelip JM. Deficient mismatch repair\/microsatellite unstable colorectal cancer: diagnosis, prognosis and treatment. Eur J Cancer. 2022;175:136\u201357. https:\/\/doi.org\/10.1016\/j.ejca.2022.07.020.","journal-title":"Eur J Cancer"},{"issue":"1","key":"4308_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.33696\/cancerimmunol.7.100","volume":"7","author":"R Miao","year":"2025","unstructured":"Miao R, Kim RD, et al. Immunotherapy in MSS\/pMMR metastatic colorectal cancer \u2013 insights from the KEYNOTE-651. J Cancer Immunol. 2025;7(1):15\u20139.","journal-title":"J Cancer Immunol"},{"issue":"8","key":"4308_CR7","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., et al.(2018). Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/\nmicrosatellite instability-high metastatic colorectal cancer. Journal of Clinical Oncology,36(8), 773\u2013779. https:\/\/doi.org\/10.1200\/JCO.2017.76.9901.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4308_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-01008-4","volume":"23","author":"L Dennison","year":"2021","unstructured":"Dennison L, Mohan AA, Yarchoan M. Tumor and systemic immunomodulatory effects of MEK inhibition. Curr Oncol Rep. 2021;23(2):23. https:\/\/doi.org\/10.1007\/s11912-020-01008-4.","journal-title":"Curr Oncol Rep"},{"key":"4308_CR9","unstructured":"The jamovi project. (2023). jamovi (Version 2.4) [Computer software]. https:\/\/www.jamovi.org"},{"issue":"6","key":"4308_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/antiox14060726","volume":"14","author":"X Zhang","year":"2025","unstructured":"Zhang X, Ye X, Jin H. Oxidized low-density lipoprotein as a potential target for enhancing immune checkpoint inhibitor therapy in microsatellite-stable colorectal cancer. Antioxidants. 2025;14(6):726. https:\/\/doi.org\/10.3390\/antiox14060726.","journal-title":"Antioxidants"},{"issue":"1","key":"4308_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-025-00361-9","volume":"6","author":"Y Jin","year":"2025","unstructured":"Jin Y, He X, Wu Y. Gastrointestinal cancer: molecular pathogenesis and targeted therapy. Mol Biomed. 2025;6(1):136. https:\/\/doi.org\/10.1186\/s43556-025-00361-9.","journal-title":"Mol Biomed"},{"issue":"9","key":"4308_CR12","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069\u201386. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0367.","journal-title":"Cancer Discov"},{"key":"4308_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.808964","volume":"12","author":"Z Bai","year":"2022","unstructured":"Bai Z, Zhou Y, Ye Z, et al. Tumor-infiltrating lymphocytes in colorectal cancer: The fundamental indication and application on immunotherapy. Front Immunol. 2022;12:808964. https:\/\/doi.org\/10.3389\/fimmu.2021.808964.","journal-title":"Front Immunol"},{"issue":"4","key":"4308_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14041028","volume":"14","author":"L Carlsen","year":"2022","unstructured":"Carlsen L, Huntington KE, El-Deiry WS. Immunotherapy for colorectal cancer: mechanisms and predictive biomarkers. Cancers (Basel). 2022;14(4):1028. https:\/\/doi.org\/10.3390\/cancers14041028.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4308_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01294-4","volume":"15","author":"J Weng","year":"2022","unstructured":"Weng J, Li S, Zhu Z, et al. Exploring immunotherapy in colorectal cancer. J Hematol Oncol. 2022;15(1):95. https:\/\/doi.org\/10.1186\/s13045-022-01294-4.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"4308_CR16","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1002\/cac2.12605","volume":"44","author":"S Zeng","year":"2024","unstructured":"Zeng S, Hu H, Li Z, et al. Local TSH\/TSHR signaling promotes CD8+ T cell exhaustion and immune evasion in colorectal carcinoma. Cancer Commun. 2024;44(11):1287\u2013310. https:\/\/doi.org\/10.1002\/cac2.12605.","journal-title":"Cancer Commun"},{"issue":"10","key":"4308_CR17","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.annonc.2022.06.008","volume":"33","author":"T Andr\u00e9","year":"2022","unstructured":"Andr\u00e9, T., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., et al. (2022).Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate142. Annals of Oncology, 33(10), 1052\u20131060. https:\/\/doi.org\/10.1016\/j.annonc.2022.06.008.","journal-title":"Ann Oncol"},{"issue":"2","key":"4308_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1200\/JCO.21.01015","volume":"40","author":"HJ Lenz","year":"2022","unstructured":"Lenz HJ, Van Cutsem E, Luisa Limon M, et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II checkmate 142 study. J Clin Oncol. 2022;40(2):161\u201370. https:\/\/doi.org\/10.1200\/JCO.21.01015.","journal-title":"J Clin Oncol"},{"key":"4308_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-026-04177-7","author":"MR Keivany","year":"2026","unstructured":"Keivany MR, Shojae E, Besharatloo M, et al. Advances in immunotherapy for colorectal cancer: overcoming resistance in mismatch repair-proficient tumors. Cancer Cell Int. 2026. https:\/\/doi.org\/10.1186\/s12935-026-04177-7.","journal-title":"Cancer Cell Int"},{"key":"4308_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1112276","volume":"13","author":"J Ros","year":"2023","unstructured":"Ros, J., Balconi, F., Baraibar, I., Saoudi Gonzalez, N., Salva, F., Tabernero, J., et al. (2023).Advances in immune checkpoint inhibitor combination strategies for microsatellite stablecolorectal cancer. Frontiers in Oncology, 13, 1112276. https:\/\/doi.org\/10.3389\/fonc.2023.1112276.","journal-title":"Front Oncol"},{"issue":"21","key":"4308_CR21","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","volume":"390","author":"M Chalabi","year":"2024","unstructured":"Chalabi, M., Verschoor, Y. L., Tan, P. B., Nielsen, M., Grootscholten, C., Aalbers, A. G. J., et al.(2024). Neoadjuvant immunotherapy in locally advanced mismatch repair\u2013deficient coloncancer. New England Journal of Medicine, 390(21), 1949\u20131958. https:\/\/doi.org\/10.1056\/NEJMoa2400634.","journal-title":"N Engl J Med"},{"issue":"1","key":"4308_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41590-020-00818-9","volume":"22","author":"V Verma","year":"2021","unstructured":"Verma, V., Jafarzadeh, N., Boi, S., Kundu, S., Jiang, Z., Fan, Y., et al. (2021). MEK inhibitionreprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects. NatureImmunology, 22(1), 53\u201366. https:\/\/doi.org\/10.1038\/s41590-020-00818-9.","journal-title":"Nat Immunol"},{"key":"4308_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00091","volume":"10","author":"AR Almutairi","year":"2020","unstructured":"Almutairi AR, McBride A, Slack M, et al. Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis. Front Oncol. 2020;10:91. https:\/\/doi.org\/10.3389\/fonc.2020.00091.","journal-title":"Front Oncol"},{"key":"4308_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00258","volume":"10","author":"R Park","year":"2020","unstructured":"Park R, Lopes L, Cristancho CR, et al. Treatment-related adverse events of combination immune checkpoint inhibitors: systematic review and meta-analysis. Front Oncol. 2020;10:258. https:\/\/doi.org\/10.3389\/fonc.2020.00258.","journal-title":"Front Oncol"},{"key":"4308_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211058393","volume":"14","author":"K Somekawa","year":"2022","unstructured":"Somekawa, K., Horita, N., Kaneko, A., Shibata, K., Sato, Y., Watanabe, T., et al. (2022).Adverse events induced by nivolumab and ipilimumab combination regimens. TherapeuticAdvances in Medical Oncology, 14, 17588359211058393. https:\/\/doi.org\/10.1177\/17588359211058393.","journal-title":"Ther Adv Med Oncol"},{"key":"4308_CR26","unstructured":"R Core Team. (2022). R: A language and environment for statistical computing (Version 4.1) [Computer software]. https:\/\/cran.r-project.org"},{"key":"4308_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W, et al. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1\u201348.","journal-title":"J Stat Softw"},{"issue":"9","key":"4308_CR28","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., et al.(2017). Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatelliteinstability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study.The Lancet Oncology, 18(9), 1182\u20131191. https:\/\/doi.org\/10.1016\/S1470-2045(17)30422-9.","journal-title":"Lancet Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04308-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04308-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04308-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T11:04:42Z","timestamp":1787396682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04308-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["4308"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04308-6","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}